Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.

NCT05631886 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT05631886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
July 4, 2023
Completion date
December 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epha2 overexpression, lymphoma, solid tumor, adult, tp53 r175h, tp53 r248q, tp53 r249s, tp53 r273h